JW Lifescience Statistics

Total Valuation

JW Lifescience has a market cap or net worth of KRW 173.74 billion. The enterprise value is 233.35 billion.

Market Cap	173.74B
Enterprise Value	233.35B

Important Dates

The last earnings date was Monday, March 24, 2025.

Earnings Date	Mar 24, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

JW Lifescience has 15.48 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	15.48M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	1.09%
Float	8.56M

Valuation Ratios

The trailing PE ratio is 3.95.

PE Ratio	3.95
Forward PE	n/a
PS Ratio	0.78
PB Ratio	0.87
P/TBV Ratio	1.41
P/FCF Ratio	4.30
P/OCF Ratio	3.43
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.76, with an EV/FCF ratio of 5.78.

EV / Earnings	5.30
EV / Sales	1.05
EV / EBITDA	3.76
EV / EBIT	5.05
EV / FCF	5.78

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.35.

Current Ratio	1.32
Quick Ratio	0.87
Debt / Equity	0.35
Debt / EBITDA	1.34
Debt / FCF	1.71
Interest Coverage	17.40

Financial Efficiency

Return on equity (ROE) is 24.45% and return on invested capital (ROIC) is 9.43%.

Return on Equity (ROE)	24.45%
Return on Assets (ROA)	7.71%
Return on Invested Capital (ROIC)	9.43%
Return on Capital Employed (ROCE)	14.63%
Revenue Per Employee	739.13M
Profits Per Employee	146.14M
Employee Count	301
Asset Turnover	0.77
Inventory Turnover	5.61

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.76% in the last 52 weeks. The beta is 0.47, so JW Lifescience's price volatility has been lower than the market average.

Beta (5Y)	0.47
52-Week Price Change	-5.76%
50-Day Moving Average	10,874.80
200-Day Moving Average	11,191.55
Relative Strength Index (RSI)	56.64
Average Volume (20 Days)	36,279

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, JW Lifescience had revenue of KRW 222.48 billion and earned 43.99 billion in profits. Earnings per share was 2,840.74.

Revenue	222.48B
Gross Profit	57.47B
Operating Income	35.86B
Pretax Income	59.03B
Net Income	43.99B
EBITDA	51.60B
EBIT	35.86B
Earnings Per Share (EPS)	2,840.74

Full Income Statement

Balance Sheet

The company has 9.62 billion in cash and 69.24 billion in debt, giving a net cash position of -59.62 billion or -3,850.03 per share.

Cash & Cash Equivalents	9.62B
Total Debt	69.24B
Net Cash	-59.62B
Net Cash Per Share	-3,850.03
Equity (Book Value)	200.44B
Book Value Per Share	12,944.82
Working Capital	25.48B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 50.69 billion and capital expenditures -10.31 billion, giving a free cash flow of 40.38 billion.

Operating Cash Flow	50.69B
Capital Expenditures	-10.31B
Free Cash Flow	40.38B
FCF Per Share	2,607.96

Full Cash Flow Statement

Margins

Gross margin is 25.83%, with operating and profit margins of 16.12% and 19.77%.

Gross Margin	25.83%
Operating Margin	16.12%
Pretax Margin	26.53%
Profit Margin	19.77%
EBITDA Margin	23.19%
EBIT Margin	16.12%
FCF Margin	18.15%

Dividends & Yields

This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 4.51%.

Dividend Per Share	500.00
Dividend Yield	4.51%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	17.60%
Buyback Yield	n/a
Shareholder Yield	4.51%
Earnings Yield	25.32%
FCF Yield	23.24%

Dividend Details

Stock Splits

The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.

Last Split Date	Apr 20, 2018
Split Type	Forward
Split Ratio	2

Scores

JW Lifescience has an Altman Z-Score of 2.6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.6
Piotroski F-Score	n/a